Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis
Abstract
Mesenchymal stem cells (MSCs) exhibit immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animals. Clinical trials in several human conditions support the safety and efficacy of MSC transplantation. Published experience in multiple sclerosis (MS) is modest.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 06, 2017
- Source ID
- 10.1177/1352458517703802
Entities
People
- Amit Bar-or
- Elizabeth M. Fisher
- Hillard M Lazarus
- Jane Reese Koc
- Jeffrey A Cohen
- Matt Karafa
- Patricia Jagodnik
- Peter B Imrey
- Robert A Bermel
- Robert J Fox
- Sarah M Planchon
- Shannon Morrison
- Stanton L. Gerson
- Susan L Sharp
- Thomai T Skaramagas
Organizations
- Biogen
- Case Western Reserve University
- Cleveland Clinic
- McGill University
- National Center for Advancing Translational Sciences
- National Institute of Neurological Disorders and Stroke
- National Multiple Sclerosis Society
- United States Department of Defense